Invivyd ( (IVVD) ) has provided an announcement.
On March 22, 2025, Invivyd, Inc. appointed Ajay Royan, founder of Mithril Capital, to its Board of Directors, with his term expiring at the 2025 annual meeting of stockholders. Royan, a venture capitalist with a focus on healthcare, technology, and energy, will receive compensation consistent with other non-employee directors and was granted an option to acquire 100,000 shares of common stock. His appointment is expected to enhance Invivyd’s efforts to advance its monoclonal antibody technology platform, which aims to provide high-quality medicines for vulnerable populations affected by COVID-19 and other diseases.
More about Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary integrated technology platform to develop best-in-class antibodies and received emergency use authorization from the U.S. FDA for a monoclonal antibody in its pipeline.
YTD Price Performance: 37.29%
Average Trading Volume: 15,872,931
Technical Sentiment Signal: Buy
Current Market Cap: $79.14M
See more insights into IVVD stock on TipRanks’ Stock Analysis page.